Heart Rate as a Therapeutic Target in Angina Pectoris

Author(s): Emmanuel Androulakis, Dimitris Tousoulis, Nikolaos Papageorgiou, Anna Kontogeorgou, Alexandros Briasoulis, Marietta Charakida, Gerasimos Siasos, Evangelos Oikonomou, Katerina Siama, George Latsios, Christodoulos Stefanadis

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 9 , 2013

Become EABM
Become Reviewer


Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.

Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [1562 - 1568]
Pages: 7
DOI: 10.2174/1381612811319090003
Price: $65

Article Metrics

PDF: 15